149 related articles for article (PubMed ID: 8047831)
1. Economic evaluation of new medical technology.
Jönsson B
Scand J Gastroenterol Suppl; 1994; 201():87-90. PubMed ID: 8047831
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation in gastrointestinal disease.
Jönsson B; Karlsson G
Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Barradell LB; McTavish D
Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Belousov IuB; Karpov OI; Belousov DIu; Beketov AS
Ter Arkh; 2007; 79(2):58-66. PubMed ID: 17460971
[No Abstract] [Full Text] [Related]
6. Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis.
Bloom BS; Hillman AL; LaMont B; Liss C; Schwartz JS; Stever GJ
Pharmacoeconomics; 1995 Oct; 8(4):343-9. PubMed ID: 10155675
[TBL] [Abstract][Full Text] [Related]
7. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture.
Stal JM; Gregor JC; Preiksaitis HG; Reynolds RP
Can J Gastroenterol; 1998; 12(1):43-9. PubMed ID: 9544411
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the cost-efficacy ratio of omeprazole and ranitidine in the treatment of reflux esophagitis].
Bergmann JF; Hamelin B; Barbier JP
Gastroenterol Clin Biol; 1995 May; 19(5):482-6. PubMed ID: 7589999
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
10. Cost of acid peptic disorders in a managed-care organization.
Segal R; Russell WL; Ben-Joseph R; Mansheim B
Clin Ther; 1996; 18(2):319-33; discussion 302. PubMed ID: 8733992
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer.
Sonnenberg A; Pauly MP; Levenson SD; Schwartz JS
Am J Manag Care; 1999 Jan; 5(1):53-9. PubMed ID: 10345967
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease.
Hillman AL
Scand J Gastroenterol Suppl; 1994; 201():98-102. PubMed ID: 8047833
[TBL] [Abstract][Full Text] [Related]
13. Pharmaco-economic considerations in the long-term management of peptic ulcer disease.
Ruszniewski P
Aliment Pharmacol Ther; 1993; 7 Suppl 2():41-8. PubMed ID: 8103375
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the cost of maintenance therapy (6 months) with 150 mg ranitidine vs 20 mg omeprazole vs 20 mg omeprazole every other day in duodenal ulcer].
Di Mario F; Grasso GA; Battaglia G; De Boni M; Vianello F; De Bona M; Pasquino M; Chiozzini G; Saggioro A
Minerva Gastroenterol Dietol; 1993 Jun; 39(2):83-7. PubMed ID: 8364105
[TBL] [Abstract][Full Text] [Related]
15. Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer.
Walan A; Eriksson S
Scand J Gastroenterol Suppl; 1994; 201():91-7. PubMed ID: 8047832
[TBL] [Abstract][Full Text] [Related]
16. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists.
Jensen DM
Am J Med; 1986 Oct; 81(4B):42-8. PubMed ID: 2877574
[TBL] [Abstract][Full Text] [Related]
17. Cost and quality effects of treating erosive oesophagitis. A re-evaluation.
Bloom BS
Pharmacoeconomics; 1995 Aug; 8(2):139-46. PubMed ID: 10155608
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis.
Eggleston A; Wigerinck A; Huijghebaert S; Dubois D; Haycox A
Gut; 1998 Jan; 42(1):13-6. PubMed ID: 9505878
[TBL] [Abstract][Full Text] [Related]
19. Economic assessment of peptic ulcer disease treatments.
Jensen DM
Scand J Gastroenterol Suppl; 1988; 146():214-24. PubMed ID: 2906466
[TBL] [Abstract][Full Text] [Related]
20. Management of nonsteroidal anti-inflammatory drug-associated lesions: a cost-effectiveness perspective.
Jönsson B; Wahlqvist P
Am J Med; 1998 Mar; 104(3A):81S-88S. PubMed ID: 9572326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
